BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 23922227)

  • 41. [Effectiveness of plerixafor in patients undergoing mobilization autologous haematopoietic progenitor cell].
    Ruano Camps R; Ortiz Pareja M; Vidales Mancha I; Muñoz Castillo IM; Heiniger Mazo AI
    Farm Hosp; 2013; 37(4):317-21. PubMed ID: 24010693
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Comparison of Plerixafor or Cyclophosphamide Combined with G-CSF in Mobilization of Peripheral Blood Stem Cells in Multiple Myeloma].
    Li WT; Ma LM; Lian Y; Wang QG; Gao ZJ; Zhao S
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1403-1409. PubMed ID: 37846691
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma.
    Lanza F; Lemoli RM; Olivieri A; Laszlo D; Martino M; Specchia G; Pavone V; Imola M; Pasini A; Milone G; Scortechini I; Todisco E; Guggiari E; Cascavilla N; Martinelli G; Rambaldi A; Bosi A
    Transfusion; 2014 Feb; 54(2):331-9. PubMed ID: 23781769
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF.
    D'Addio A; Curti A; Worel N; Douglas K; Motta MR; Rizzi S; Dan E; Taioli S; Giudice V; Agis H; Kopetzky G; Soutar R; Casadei B; Baccarani M; Lemoli RM
    Bone Marrow Transplant; 2011 Mar; 46(3):356-63. PubMed ID: 20577218
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Plerixafor for mobilization of blood stem cells in autologous transplantation: an update.
    Jantunen E; Varmavuo V
    Expert Opin Biol Ther; 2014 Jun; 14(6):851-61. PubMed ID: 24673120
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mobilization of PBSCs in poor mobilizers with POEMS syndrome using G-CSF with plerixafor.
    Shimizu N; Sakaida E; Ohwada C; Takeuchi M; Kawaguchi T; Tsukamoto S; Sakai S; Takeda Y; Sugita Y; Yokote K; Iseki T; Isose S; Kanai K; Misawa S; Kuwabara S; Nakaseko C
    Bone Marrow Transplant; 2012 Dec; 47(12):1587-8. PubMed ID: 22609884
    [No Abstract]   [Full Text] [Related]  

  • 47. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
    Steinberg M; Silva M
    Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Second time a charm? Remobilization of peripheral blood stem cells with plerixafor in patients who previously mobilized poorly despite using plerixafor as a salvage agent.
    Yuan S; Nademanee A; Krishnan A; Kogut N; Shayani S; Wang S
    Transfusion; 2013 Dec; 53(12):3244-50. PubMed ID: 23607889
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Optimizing mobilization strategies in difficult-to-mobilize patients: The role of plerixafor.
    Goker H; Etgul S; Buyukasik Y
    Transfus Apher Sci; 2015 Aug; 53(1):23-9. PubMed ID: 26099666
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Differences in Cellular Composition of Peripheral Blood Stem Cell Grafts from Healthy Stem Cell Donors Mobilized with Either Granulocyte Colony-Stimulating Factor (G-CSF) Alone or G-CSF and Plerixafor.
    Teipel R; Oelschlägel U; Wetzko K; Schmiedgen M; Kramer M; Rücker-Braun E; Hölig K; von Bonin M; Heidrich K; Fuchs A; Ordemann R; Kroschinsky F; Bornhäuser M; Hütter G; Schmidt H; Ehninger G; Schetelig J; Heidenreich F
    Biol Blood Marrow Transplant; 2018 Nov; 24(11):2171-2177. PubMed ID: 29935214
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience.
    Jantunen E; Kuittinen T; Mahlamäki E; Pyörälä M; Mäntymaa P; Nousiainen T
    Eur J Haematol; 2011 Apr; 86(4):299-304. PubMed ID: 21198864
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial.
    Jagirdar N; Harvey RD; Nooka A; Flowers C; Kaufman J; Lonial S; Lechowicz MJ; Langston A; Lipscomb C; Gaylor C; Waller EK
    Transfusion; 2015 Oct; 55(10):2351-7. PubMed ID: 26331348
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization.
    Dugan MJ; Maziarz RT; Bensinger WI; Nademanee A; Liesveld J; Badel K; Dehner C; Gibney C; Bridger G; Calandra G
    Bone Marrow Transplant; 2010 Jan; 45(1):39-47. PubMed ID: 19483760
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Pilot, Exploratory, Randomized, Phase II Safety Study Evaluating Tumor Cell Mobilization and Apheresis Product Contamination in Patients Treated with Granulocyte Colony-Stimulating Factor Alone or Plus Plerixafor.
    Nahi H; Celanovic M; Liu Q; Lund J; Peceliunas V
    Biol Blood Marrow Transplant; 2019 Jan; 25(1):34-40. PubMed ID: 30149148
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The efficacy of residual plerixafor for second-day stem cell mobilization in multiple myeloma patients.
    He D; Zhu C; Guo X; Huang X; Han X; Zheng G; Zhao Y; Yang Y; Wu W; Ge J; Zhang E; He J; Cai Z
    Transfus Apher Sci; 2023 Jun; 62(3):103618. PubMed ID: 36481258
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Plerixafor plus pegfilgrastim is a safe, effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells: a phase I clinical trial.
    Herbert KE; Demosthenous L; Wiesner G; Link E; Westerman DA; Came N; Ritchie DS; Harrison S; Seymour JF; Prince HM
    Bone Marrow Transplant; 2014 Aug; 49(8):1056-62. PubMed ID: 24887382
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Novel strategies for blood stem cell mobilization: special focus on plerixafor.
    Jantunen E
    Expert Opin Biol Ther; 2011 Sep; 11(9):1241-8. PubMed ID: 21806478
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Chemotherapy-based versus chemotherapy-free stem cell mobilization (± plerixafor) in multiple myeloma patients: an Italian cost-effectiveness analysis.
    Lazzaro C; Castagna L; Lanza F; Laszlo D; Milone G; Pierelli L; Saccardi R
    Bone Marrow Transplant; 2021 Aug; 56(8):1876-1887. PubMed ID: 33753907
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Use of Plerixafor with Granulocyte Colony-Stimulating Factor for Stem Cell Mobilization in a Pediatric Patient.
    Bernardo VA; Ng JS; Joyce MJ
    Ann Pharmacother; 2011 Feb; 45(2):e12. PubMed ID: 21285407
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation.
    Elayan MM; Horowitz JG; Magraner JM; Shaughnessy PJ; Bachier C
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1921-5. PubMed ID: 26033279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.